应用门冬氨酸钾镁治疗急性心肌梗死的疗效观察

目的 :探讨门冬氨酸钾镁在急性心肌梗死治疗中的应用价值。方法 :采用随机、单盲将 12 6例急性心肌梗死患者分为门冬氨酸钾镁治疗组和对照组 ,治疗组在急性心肌梗死的当日 ,静滴门冬氨酸钾镁 10 0ml,第 2～ 5日静滴剂量每日 5 0ml ,第 6日改为口服。观察两组 1个月内心律失常、心力衰竭的发生率和病死率。结果 :治疗组与对照组恶性心律失常发生率分别为 11%和 2 6% (P <0 .0 5 ) ;心衰发生率分别为 11%和 2 8% (P <0 .0 5 ) ;1个月内病死率分别为 9%和 2 5 % (P <0 .0 5 )。结论 :在急性心肌梗死中应用门冬氨酸钾镁可有效降低恶性心律失常和心衰发生

The Clinical Observation of Potassium Magnesium Aspartate in the Treatment of Acute Myocardial Infarction

Objective:To observe the benefits of potassium-magnesium aspartate in acute myocardial infarction .Methods:One hundred and twenty-six patients were prospectively ,randomly assigned in a one-blind fashion to receive intravenous potassium-magnesium aspartate (magnesium group, n=61)or controls (placebo group, n=65). We prospectively examined the effect of potassium-magnesium aspartate treatment on the incidence of arrhythmia and heart failure ,and the mortality in hospital .Results:The morbility of arrhythmia in magnesium and placebo group were 11% and 26% (P<0 05), respectively ;the incidence of heart failure in the two groups were 11% and 26% (P<0.05), respectively, the incidence of heart failure in the two groups were 11% and 28% (P<0.05), respectively, and the the mortality in the two groups were 8.2% and 20% (P<0.05), respectively .Conclusions:Potassium-magnesium aspartate is a safe and useful therapy in reducing the incidence of arrhythmia, heart failure and the mortality after acute myocardial infarction.